Filing Flows › Health Care › Entrada Therapeutics (TRDA)
Entrada Therapeutics (TRDA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Entrada Therapeutics (TRDA) Q3 2026 earnings results →
Q3 2026 Revenue down 44% year over year to $905K
Entrada Therapeutics made $905K in Q3 2026 (-44% Y/Y). Operating margin n/m, net loss $39.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $905K in Q3 2026, down 44% year over year and up 1% from the previous quarter.
Operating costs exceeded revenue by $41.7M, an operating margin of -4606.5%. Total costs fell 12% while revenue fell 44%. The quarter ended with a net loss of $39.7M, narrower than the previous quarter's $42.8M loss.
Operating cash flow was −$30.0M. Non-cash charges added back $700K of depreciation and $4.8M of share-based compensation. Working capital and other items added $4.3M. Capital expenditures of $161K exceeded it, leaving free cash flow of −$30.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $905K | -44% | n/m | −$39.7M | −$30.0M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $898K | -54% | n/m | −$42.8M | −$32.5M |
| Q1 2026 | 10-Q | May 7, 2026 | $875K | -96% | n/m | −$39.7M | −$41.7M |
| Q4 2025 | 10-K | Feb 26, 2026 | $1.3M | -96% | n/m | −$39.2M | −$32.2M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $1.6M | -92% | n/m | −$44.1M | −$28.3M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $1.9M | -98% | n/m | −$43.1M | −$29.5M |
| Q1 2025 | 10-Q | May 8, 2025 | $20.6M | -65% | -106.0% | −$17.3M | −$38.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Entrada Therapeutics
We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by e stablishing a new class of medicines that engage intracellular targets that have long been considered inaccessible . Through proprietary, versatile and modular approaches, we are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. In 2026, we expect to progress our ENTR-601-44 and ENTR-601-45 clinical trials, an EU filing for the ENTR-601-50 clinical trial, and regulatory submissions for ENTR-601-51. In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated (“Vertex”) continues to progress, with dosing completion anticipated in mid-2026.
In its own words, from its 10-K, filed Feb 26, 2026.
Entrada Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -44% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TRDA Entrada Therapeutics | Q3 2026 | $905K | -44% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Entrada Therapeutics 10-Q on SEC EDGAR · CIK 1689375 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns TRDA and who is buying
More on TRDA
- How Entrada Therapeutics makes money: revenue by segment
- Entrada Therapeutics next earnings date and what analysts expect
- Entrada Therapeutics stock forecast, price target and fair value
- Who owns Entrada Therapeutics stock: holders, funds and Congress trades
- Entrada Therapeutics guidance and outlook
- Entrada Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results